ASA and ASF Announce new joint initiative in forming a Community Advisory Board.
November 2020 The International Angelman Syndrome Alliance (ASA) and the Angelman Foundation (ASF) are delighted to announce details of a newly formed joint initiative: the Global Community Advisory Board. They will work together to represent the Angelman community as a unified voice when engaging with pharmaceutical companies looking to enter research programmes. The CAB will act as a consulting service to stakeholders involved in the research, development, reimbursement and service provision of biomedical treatments or processes, including both scientific and policy-related issues. Supported by Eurodis, the European organisation for Rare Disorders, the Angelman CAB will be a group of trained advocates who use their knowledge and expertise to discuss and advise on the latest developments, challenges and issues related to medical treatments and procedures under development in in Angelman Syndrome.